Market Intelligence, Clinical Progress, and High-Purity Reagents for Leukemia and Oncogenic Fusion Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CBFA2T3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CBFA2T3 Recombinant Protein (NHR domains / Full-Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for PPI screening. |
View CBFA2T3 Products |
| Gene Delivery | CBFA2T3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and transcriptional assays. |
View CBFA2T3 Products |
| Benchmark Ab | Anti-CBFA2T3 Recombinant Antibody Recombinant positive control for Western Blot, IP, and ChIP assays. |
View CBFA2T3 Products |
| Validator | CBFA2T3 siRNA Set For target knockdown and specificity verification in cell-based models. |
View CBFA2T3 Products |
| Related Target A | GLIS2 Critical fusion partner (CBFA2T3-GLIS2) driving pediatric acute megakaryoblastic leukemia (AMKL). |
View GLIS2 Products |
| Related Target B | RUNX1 Core-binding factor subunit interacting with CBFA2T3 in hematopoiesis and leukemia pathways. |
View RUNX1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (e.g., CBFA2T3-GLIS2 or ETO complexes) | High-purity recombinant CBFA2T3 proteins (>95% by SDS-PAGE) with precise NHR domain truncations. |
| In cellulo transcriptional activity validation | Lentiviral particles expressing full-length CBFA2T3 or CBFA2T3-GLIS2 fusion transcripts with verified sequences. |
| Lack of reliable assay controls | Sequence-verified recombinant benchmark antibodies and validated siRNA sets included in the assay panel. |
| Off-target assay noise and false positives | Strict endotoxin control (<1.0 EU/μg) and mass spectrometry-verified molecular weight. |
Live CBFA2T3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CBFA2T3 therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapies to targeted protein-protein interaction (PPI) disruptors and targeted protein degradation (PROTACs). As first-generation molecular fusions involving CBFA2T3 (such as CBFA2T3-GLIS2 in pediatric acute megakaryoblastic leukemia) are characterized as high-risk oncogenic drivers, the next wave of R&D is targeting these specific fusion interfaces to rescue normal hematopoiesis and induce apoptosis in refractory AML subsets.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Emerging Biopharma | Pediatric AMKL, Acute Myeloid Leukemia (AML) | High-purity recombinant domains for TR-FRET/FP assays (Need stable, soluble CBFA2T3/GLIS2 proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | CBFA2T3-GLIS2 Positive Leukemias | Ubiquitination assays and Western Blot validation (Need sequence-verified antibodies & custom mutants) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Refractory Pediatric Hematological Malignancies | Target knockdown validation (Need validated siRNA sets and lentivirus-driven reporter lines) |